Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.

María Del Mar Noblejas-LópezCristina Nieto-JimenezMiguel BurgosMónica Gómez-JuárezJuan Carlos MonteroAzucena Esparís-OgandoAtanasio PandiellaEva Maria Galan-Moya Alberto Ocaña

Published in: Journal of experimental & clinical cancer research : CR (2019)

Using both in vitro and in vivo approaches, we describe the profound activity of BET-PROTACs in parental and BETi-resistant TNBC models. This data provides options for further clinical development of these agents in TNBC.

Keyphrases

cell therapy
electronic health record
intellectual disability
cancer therapy
stem cells
mesenchymal stem cells
bone marrow
drug delivery